These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Nimer SD J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Talati C; Sallman D; List A Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290 [TBL] [Abstract][Full Text] [Related]
9. Megakaryocytopoiesis in patients with myelodysplastic syndromes (MDS) with and without del(5q). Podolak-Dawidziak M; Geddes D; Bowen D Eur J Haematol; 1990 Aug; 45(2):115-6. PubMed ID: 2271049 [No Abstract] [Full Text] [Related]
10. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924 [TBL] [Abstract][Full Text] [Related]
11. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Kumar MS; Narla A; Nonami A; Mullally A; Dimitrova N; Ball B; McAuley JR; Poveromo L; Kutok JL; Galili N; Raza A; Attar E; Gilliland DG; Jacks T; Ebert BL Blood; 2011 Oct; 118(17):4666-73. PubMed ID: 21873545 [TBL] [Abstract][Full Text] [Related]
12. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome. Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631 [TBL] [Abstract][Full Text] [Related]
13. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study. Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461 [TBL] [Abstract][Full Text] [Related]
14. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949 [TBL] [Abstract][Full Text] [Related]
15. Genetic deletions in AML and MDS. Ebert BL Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407 [TBL] [Abstract][Full Text] [Related]